Source comparison
PT-141 Interactions: Comparison of Medication Classes and Risk Profiles
The table below summarises the most clinically significant PT-141 interactions documented in clinical trials, preclinical studies, and pharmacokinetic modelling. Each row represents a medication or substance class, the mechanism of interaction, the documented
This comparison does not assign a generated winner or score.
- The table below summarises the most clinically significant PT-141 interactions documented in clinical trials, preclinical studies, and pharmacokinetic modelling. Each row represents a medication or substance class, the mechanism of interaction, the documented effect on PT-141 efficacy or safety, and a professional assessment of the risk level for research protocols.
- ACE inhibitors (lisinopril, enalapril)
- Pharmacodynamic opposition. Peripheral vasodilation vs centrally mediated vasoconstriction
- Unpredictable blood pressure fluctuation, transient hypertensive spikes in 12% of co-administered subjects
- 24 hours minimum
- Moderate risk. Monitor blood pressure continuously for 6 hours post-dose
- Calcium channel blockers (amlodipine, diltiazem)
- Additive vasodilation during overlapping plasma concentration windows
- Symptomatic hypotension in 8% of subjects when dosed within 4 hours
- 6–12 hours
- Low to moderate risk. Stagger dosing to avoid peak overlap
- Beta-blockers (metoprolol, atenolol)
- Blunted compensatory tachycardia in response to PT-141's blood pressure effects
- Reduced ability to compensate for transient hypertension, dizziness reported in 15%
- 12–24 hours
- Moderate risk. Beta-blockade impairs autonomic response
- Melanotan II
- Competitive melanocortin receptor binding (MC3R, MC4R)
- Receptor saturation, no additive benefit, 22% increase in mean arterial pressure
- 48 hours
- High risk. Redundant mechanism, amplified cardiovascular strain
- GLP-1 agonists (semaglutide, tirzepatide)
- Additive gastrointestinal effects (nausea, delayed gastric emptying)
- Increased nausea incidence (40–50% vs 25% baseline), no pharmacokinetic interference
- 6 hours
- Low risk for pharmacokinetics, moderate for adverse events
- Alcohol (ethanol)
- Impaired baroreceptor reflex, additive vasodilation
- Orthostatic hypotension, flushing, dizziness in moderate drinkers (2–3 drinks within 4 hours)
- 12 hours minimum
- Moderate to high risk. Unpredictable autonomic response
- Benzodiazepines (lorazepam, diazepam)
- Opposing effects on arousal states (GABA agonism vs melanocortin activation)
- Blunted PT-141 efficacy on arousal endpoints, no safety interaction documented
- 48 hours if feasible
- Low safety risk, high confounding risk for efficacy studies
- Opioids (morphine, oxycodone)
- Chronic downregulation of MC4R receptor density
- Reduced PT-141 efficacy in chronic users, no acute interaction
- N/A. Chronic effect
- Moderate risk. Exclude chronic users from efficacy protocols